Health & Fitness
Tue, October 30, 2012Mon, October 29, 2012Sun, October 28, 2012Fri, October 26, 2012Thu, October 25, 2012Wed, October 24, 2012Tue, October 23, 2012Mon, October 22, 2012Sun, October 21, 2012Sat, October 20, 2012Fri, October 19, 2012Thu, October 18, 2012Wed, October 17, 2012Tue, October 16, 2012Mon, October 15, 2012Sun, October 14, 2012Fri, October 12, 2012Thu, October 11, 2012Wed, October 10, 2012Tue, October 9, 2012Mon, October 8, 2012Sun, October 7, 2012Sat, October 6, 2012Fri, October 5, 2012Thu, October 4, 2012Wed, October 3, 2012MAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX Orally Inhaled Migraine Drug
//health-fitness.news-articles.net/content/2012/ .. da-for-levadex-orally-inhaled-migraine-drug.html
Published in Health and Fitness on Tuesday, October 16th 2012 at 4:15 GMT by Market WireMAP Pharmaceuticals Resubmits New Drug Application to FDA for LEVADEX Orally... -- MOUNTAIN VIEW, Calif., Oct. 16, 2012 /PRNewswire/ --
MOUNTAIN VIEW, Calif., Oct. 16, 2012 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: [ MAPP ]) today announced that it has resubmitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults.
"We have worked diligently on our LEVADEX resubmission and, based on our dialogue with the FDA, we believe that we have addressed the issues outlined by the FDA in the Complete Response letter we received in March 2012," said Timothy S. Nelson , president and chief executive officer of MAP Pharmaceuticals. "We continue to dedicate ourselves to making this potential new treatment for migraine sufferers available to many of the millions of patients whose migraines are not well treated with the options available today."
About MAP Pharmaceuticals
MAP Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing new therapies to address undermet patient needs in neurology. The Company is developing LEVADEX®, an orally inhaled investigational drug for the acute treatment of migraine. The U.S. Food and Drug Administration (FDA) reviewed the New Drug Application (NDA) for LEVADEX and on March 26, 2012, the Company received a Complete Response letter with respect to this NDA. MAP Pharmaceuticals has entered into a collaboration agreement with Allergan, Inc. to co-promote LEVADEX to neurologists and pain specialists in the U.S. and Canada. The Company also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history. Additional information about MAP Pharmaceuticals can be found at [ http://www.mappharma.com ].
CONTACT: Christopher Y. Chai, Sr. Vice President and Chief Financial Officer of MAP Pharmaceuticals, Inc., (650) 386-3107; or media, Lisa Borland , (650) 386-3122, [ lborland@mappharma.com ].
SOURCE MAP Pharmaceuticals, Inc.
